The webinar will highlight Alliance for Clinical Trials in Oncology and Alliance Foundation Trials research recently presented at the American Society of Hematology (ASH) and the San Antonio Breast Cancer Symposium (SABCS). The webinar will showcase Alliance key findings and clinical trial results from the meetings. Moderated by Alliance Group Chair Evanthia Galanis, MD, and Alliance Central Protocol Operations Program Director and Principal Investigator Olwen Hahn, MD, panelists include:
A. Marilyn Leitch, MD (UT Southwestern Medical Center) presenting results from the ALTERNATE trial (Alliance A011106), a randomized phase III study of neoadjuvant endocrine therapy (hormone targeting medicine) in postmenopausal women with clinical stage II/III breast cancer.
Andrew Yee, MD (Massachusetts General Hospital) discussing results from AFT-41, a randomized phase II study of daratumumab (immunotherapy), lenalidomide (immunomodulatory drug), ixazomib (cancer medication) and dexamethasone (steroid) in transplant-ineligible or deferred patients with multiple myeloma.
Otto Metzger, MD (Dana-Farber Cancer Institute) discussing the central nervous system outcomes from the phase III PATINA trial (AFT-38), a randomized, open label clinical study on the use of palbociclib (cancer growth blocker) for metastatic breast cancer.
Matthew J. Wieduwilt, MD (Wake Forest School of Medicine) presenting results from Alliance A041703, a phase II trial using inotuzumab ozogamicin (targeted therapy) then blinatumomab (immunotherapy) for older adults with newly diagnosed, Ph-negative, CD22-positive, B-cell acute lymphoblastic leukemia.
In addition to the investigators, Alliance Patient Advocate Committee members will join the panel to discuss the importance of each trial from a patient’s perspective.
While the Alliance for Clinical Trials in Oncology strives to provide accurate and up-to-date information, this information may change quickly and become out-of-date or incomplete. The content of the video is as current as of the publication date - March 16, 2026.
Runtime 01:02:41
